Srilatha Edupuganti is an Infectious Disease physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
80 Jesse Hill Jr Dr SE
Atlanta, GA 303033031
Telephone
404-778-7717Registry record last updated 8 Jul 2007.
Clinical trials
- Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Characterization of Human Memory Immune Responses to Prior Yellow Fever Vaccination
Sponsor: Emory University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ViiV Healthcare CompanyProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2019–2026 per NIH RePORTER. The latest:
- A Phase 2b randomized open label trial to assess the quality and balance of dengue immunity elicited by prime-boost combinations of TAK-003 and Butantan-DV
Emory University
FY2026$666,595U01AI186860 - A Phase 2b randomized open label trial to assess the quality and balance of dengue immunity elicited by prime-boost combinations of TAK-003 and Butantan-DV
Emory University
FY2025$578,157U01AI186860 - A Phase 2b randomized open label trial to assess the quality and balance of dengue immunity elicited by prime-boost combinations of TAK-003 and Butantan-DV
Emory University
FY2025$299,430U01AI186860
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”